Zacks Investment Research lowered shares of Amedisys (NASDAQ:AMED) from a buy rating to a hold rating in a report released on Tuesday morning.
According to Zacks, “Over the past three months, Amedisys has been outperforming its broader industry. The company witnessing encouraging growth in Medicare and non-Medicare revenues at the Home Health and Hospice divisions buoys optimism. Amedisys is currently exploring opportunities in these segments. We are also upbeat about the company’s solid performance in the recently-launched Personal Care segment. A favorable demographic trend and strategic acquisitions bode well for the company. However, escalating operating expenses and declining gross margin continue to raise concerns. Also, an intense competitive landscape and regulatory concerns continue to pose challenges in the home health and hospice industry.”
Several other analysts have also commented on AMED. BidaskClub raised shares of Amedisys from a hold rating to a buy rating in a research report on Thursday, March 15th. Jefferies Group set a $70.00 price objective on shares of Amedisys and gave the stock a buy rating in a research report on Wednesday, February 28th. Royal Bank of Canada raised shares of Amedisys from a sector perform rating to an outperform rating in a research report on Monday, March 19th. Oppenheimer lifted their price objective on shares of Amedisys from $68.00 to $63.00 and gave the stock an outperform rating in a research report on Thursday, March 1st. Finally, Robert W. Baird set a $66.00 price target on shares of Amedisys and gave the company a hold rating in a research report on Thursday, March 1st. Five research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company currently has an average rating of Buy and an average price target of $63.18.
Amedisys (NASDAQ:AMED) last announced its quarterly earnings data on Tuesday, February 27th. The health services provider reported $0.56 EPS for the quarter, missing the consensus estimate of $0.58 by ($0.02). The company had revenue of $404.24 million during the quarter, compared to the consensus estimate of $394.96 million. Amedisys had a return on equity of 15.14% and a net margin of 1.98%. During the same period in the prior year, the firm posted $0.44 EPS. equities analysts forecast that Amedisys will post 3 EPS for the current year.
Several hedge funds and other institutional investors have recently bought and sold shares of AMED. Point72 Asset Management L.P. raised its position in shares of Amedisys by 337.0% in the third quarter. Point72 Asset Management L.P. now owns 474,044 shares of the health services provider’s stock valued at $26,528,000 after purchasing an additional 674,044 shares during the period. Millennium Management LLC raised its position in shares of Amedisys by 58.2% in the fourth quarter. Millennium Management LLC now owns 1,048,423 shares of the health services provider’s stock valued at $55,262,000 after purchasing an additional 385,734 shares during the period. Wells Fargo & Company MN raised its position in shares of Amedisys by 29.7% in the third quarter. Wells Fargo & Company MN now owns 1,484,041 shares of the health services provider’s stock valued at $83,048,000 after purchasing an additional 339,825 shares during the period. Two Sigma Investments LP bought a new stake in shares of Amedisys in the fourth quarter valued at approximately $8,417,000. Finally, Eaton Vance Management raised its position in shares of Amedisys by 67.2% in the fourth quarter. Eaton Vance Management now owns 338,488 shares of the health services provider’s stock valued at $17,842,000 after purchasing an additional 136,001 shares during the period. 96.71% of the stock is currently owned by institutional investors.
WARNING: This piece of content was first posted by Ticker Report and is owned by of Ticker Report. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3296238/amedisys-amed-rating-lowered-to-hold-at-zacks-investment-research.html.
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.